eMedicine Specialties > Pulmonology > Pulmonary Embolism

Pulmonary Embolism

Nader Kamangar, MD, FACP, FCCP, FAASM,, Associate Professor of Clinical Medicine, Director of Hospitalist/Intensivist Program, Division of Pulmonary, Critical Care and Sleep Medicine, David Geffen School of Medicine at University of California Los Angeles; Associate Director, Combined Pulmonary and Critical Care Fellowship Program, Cedars-Sinai/Olive View-UCLA/West Los Angeles Veterans Affairs Medical Center
Mark S McDonnell, MD, MBA, Cardiology Fellow, University of Southern California; Sat Sharma, MD, FRCPC, Professor and Head, Division of Pulmonary Medicine, Department of Internal Medicine, University of Manitoba; Site Director, Respiratory Medicine, St Boniface General Hospital

Updated: Aug 25, 2009

Introduction

Background

Pulmonary embolism (PE) is a common and potentially lethal condition. Most patients who succumb to pulmonary embolism do so within the first few hours of the event. In patients who survive, recurrent embolism and death can be prevented with prompt diagnosis and therapy. Unfortunately, the diagnosis is often missed because patients with pulmonary embolism present with nonspecific signs and symptoms. If left untreated, approximately one third of patients who survive an initial pulmonary embolism die from a subsequent embolic episode.

The most important conceptual advance regarding pulmonary embolism over the last several decades has been the realization that pulmonary embolism is not a disease; rather, pulmonary embolism is a complication of venous thromboembolism, most commonly deep venous thrombosis (DVT). Virtually every physician who is involved in patient care (eg, internist, family physician, orthopedic surgeon, gynecologic surgeon, urologic surgeon, pulmonary subspecialist, cardiologist) encounters patients who are at risk for venous thromboembolism, and therefore at risk for pulmonary embolism.

A large pulmonary artery thrombus in a hospitalized patient who died suddenly.

Pulmonary embolism was identified as the cause of death in a patient who developed shortness of breath while hospitalized for hip joint surgery. This is a close-up view.

Pathophysiology

The pathophysiology of pulmonary embolism encompasses several aspects, as described below.
 
Natural history of venous thrombosis

In the 19th century, Virchow identified a triad of factors that lead to venous thrombosis: venous stasis, injury to the intima, and enhanced coagulation properties of the blood. Thrombosis usually originates as a platelet nidus on valves in the veins of the lower extremities. Further growth occurs by accretion of platelets and fibrin and progression to red fibrin thrombus, which may either break off and embolize or result in total occlusion of the vein. The endogenous thrombolytic system leads to partial dissolution; then, the thrombus becomes organized and is incorporated into the venous wall.

Natural history of pulmonary embolism

Pulmonary emboli usually arise from the thrombi originating in the deep venous system of the lower extremities; however, rarely they may originate in the pelvic, renal, or upper extremity veins or the right heart chambers. After traveling to the lung, large thrombi can lodge at the bifurcation of the main pulmonary artery or the lobar branches and cause hemodynamic compromise. Smaller thrombi typically travel more distally, occluding smaller vessels in the lung periphery. These are more likely to produce pleuritic chest pain by initiating an inflammatory response adjacent to the parietal pleura. Most pulmonary emboli are multiple, and the lower lobes are involved more commonly than the upper lobes.

Respiratory consequences

Acute respiratory consequences of pulmonary embolism include increased alveolar dead space, pneumoconstriction, hypoxemia, and hyperventilation. Later, 2 additional consequences may occur: regional loss of surfactant and pulmonary infarction (see Media File 3). Arterial hypoxemia is a frequent but not universal finding in patients with acute embolism. The mechanisms of hypoxemia include ventilation-perfusion mismatch, intrapulmonary shunts, reduced cardiac output, and intracardiac shunt via a patent foramen ovale. Pulmonary infarction is an uncommon consequence because of the bronchial arterial collateral circulation.

Lung infarction secondary to pulmonary embolism occurs rarely.

Frequency

United States

The incidence of pulmonary embolism in the United States is estimated at 1 case per 1000 persons per year.¹ Studies from 2008 suggest that the increasing use of computed tomography (CT) for assessing patients with possible pulmonary embolism has led to an increase in the reported incidence of pulmonary embolism.^2,3

Pulmonary embolism is present in 60-80% of patients with DVT, even though more than half these patients are asymptomatic. Pulmonary embolism is the third most common cause of death in hospitalized patients, with at least 650,000 cases occurring annually. Autopsy studies have shown that approximately 60% of patients who died in the hospital had pulmonary embolism, and the diagnosis was missed in up to 70% of the cases. Prospective studies have demonstrated DVT in 10-13% of all medical patients placed on bed rest for 1 week, 29-33% of all patients in medical intensive care units, 20-26% of patients with pulmonary diseases who are given bed rest for 3 or more days, 27-33% of those admitted to a critical care unit after a myocardial infarction, and 48% of patients who are asymptomatic after a coronary artery bypass graft.

A population-based study covering the years 1966-1995 collated the cases of DVT or pulmonary embolism in women during pregnancy or postpartum. The relative risk was 4.29, and the overall incidence of venous thromboembolism (absolute risk) was 199.7 incidents per 100,000 woman-years. Among postpartum women, the annual incidence was 5 times higher than in pregnant women (511.2 vs 95.8 incidents per 100,000 women).

The incidence of DVT was 3 times higher than that of pulmonary embolism (151.8 vs 47.9 incidents per 100,000 women). Pulmonary embolism was relatively less common during pregnancy versus the postpartum period (10.6 vs 159.7 incidents per 100,000 women).⁴ A national review of severe obstetric complications from 1998-2005 found a significant increase in the rate of pulmonary embolism associated with the increasing rate of cesarean delivery.⁵

Also see Pulmonary Disease and Pregnancy.

International

The incidence of pulmonary embolism may differ substantially from country to country; observed variation is likely due to differences in the accuracy of diagnosis rather than in the actual incidence.

Mortality/Morbidity

• From 1979-1998, the age-adjusted death rate for pulmonary embolism in the United States decreased from 191 deaths per million population to 94 deaths per million population.¹  Regional studies covering more recent years have found either a slight decrease or no change in mortality.^2,3
• As a cause of sudden death, massive pulmonary embolism is second only to sudden cardiac death. Autopsy studies of patients who died unexpectedly in a hospital setting have shown approximately 80% of these patients died from massive pulmonary embolism.
• Approximately 10% of patients who develop pulmonary embolism die within the first hour, and 30% die subsequently from recurrent embolism. Anticoagulant treatment decreases the mortality rate to less than 5%.
• The diagnosis of pulmonary embolism is missed in approximately 400,000 patients in the United States per year; approximately 100,000 deaths could be prevented with proper diagnosis and treatment.

Race

• The incidence of pulmonary embolism appears to be significantly higher in blacks than in whites.⁶ Mortality rates from pulmonary embolism for blacks have been 50% higher than those for whites, and those for whites have been 50% higher than those for people of other races (eg, Asians, Native Americans).¹

Sex

• The risk of pulmonary embolism is increased in pregnancy and during the postpartum period.
• Data are conflicting regarding male sex as a risk factor for pulmonary embolism; however, an analysis of national mortality data found that death rates from pulmonary embolism were 20-30% higher among men than among women.¹

Age

• In hospitalized elderly patients, pulmonary embolism is commonly missed and often is the cause of death.

Clinical

History

The presentation of pulmonary embolism (PE) may vary from sudden catastrophic hemodynamic collapse to gradually progressive dyspnea. The diagnosis of pulmonary embolism should be sought actively in patients with respiratory symptoms unexplained by an alternate diagnosis. The symptoms of pulmonary embolism are nonspecific; therefore, a high index of suspicion is required, particularly when a patient has risk factors for the condition (see Causes, below).
The presentation of patients with pulmonary embolism can be categorized into 4 classes based on the acuity and severity of pulmonary arterial occlusion. These categories are (1) massive pulmonary embolism, (2) acute pulmonary infarction, (3) acute embolism without infarction, and (4) multiple pulmonary emboli.

• Massive pulmonary embolism
  • Large emboli compromise sufficient pulmonary circulation to produce circulatory collapse and shock.
  • The patient has hypotension; appears weak, pale, sweaty, and oliguric; and develops impaired mentation.
• Acute pulmonary infarction
  • Approximately 10% of patients have peripheral occlusion of a pulmonary artery causing parenchymal infarction.
  • These patients present with acute onset of pleuritic chest pain, breathlessness, and hemoptysis.
  • Although the chest pain may be clinically indistinguishable from ischemic myocardial pain, normal electrocardiogram findings and no response to nitroglycerin rules it out.
• Acute embolism without infarction: Patients have nonspecific symptoms of unexplained dyspnea and/or substernal discomfort.
• Multiple pulmonary emboli
  • This group comprises 2 subsets of patients.
  • The first subset has repeated documented episodes of pulmonary emboli over years, eventually presenting with signs and symptoms of pulmonary hypertension and cor pulmonale.
  • The second subset has no previously documented pulmonary emboli but has widespread obstruction of the pulmonary circulation with clot. They present with gradually progressive dyspnea, intermittent exertional chest pain, and, eventually, features of pulmonary hypertension and cor pulmonale.

Most patients with pulmonary embolism have no obvious symptoms at presentation. In contrast, patients with symptomatic DVT commonly have pulmonary embolism confirmed on diagnostic studies in the absence of pulmonary symptoms.

The most common symptoms of pulmonary embolism in the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) study were dyspnea (73%), pleuritic chest pain (66%), cough (37%), and hemoptysis (13%).⁷ However, patients with pulmonary embolism may present with atypical symptoms. In such cases, strong suspicion of pulmonary embolism based on the presence of risk factors can lead to consideration of pulmonary embolism in the differential diagnosis. These symptoms include the following:  

• Seizures
• Syncope
• Abdominal pain
• Fever
• Productive cough
• Wheezing
• Decreasing level of consciousness
• New onset of atrial fibrillation
• Flank pain⁸
• Delirium (in elderly patients)⁹

Pleuritic chest pain without other symptoms or risk factors may be a presentation of pulmonary embolism.

Physical

Physical examination findings are quite variable in pulmonary embolism and, for convenience, may be grouped into 4 categories as follows:

• Massive pulmonary embolism
  • These patients are in shock. They have systemic hypotension, poor perfusion of the extremities, tachycardia, and tachypnea.
  • Additionally, signs of pulmonary hypertension such as palpable impulse over the second left intercostal space, loud P2, right ventricular S3 gallop, and a systolic murmur louder on inspiration at left sternal border (tricuspid regurgitation) may be present.
• Acute pulmonary infarction
  • These patients have decreased excursion of the involved hemithorax, palpable or audible pleural friction rub, and even localized tenderness.
  • Signs of pleural effusion, such as dullness to percussion and diminished breath sounds, may be present.
• Acute embolism without infarction
  • These patients have nonspecific physical signs that may easily be secondary to another disease process.
  • Tachypnea and tachycardia frequently are detected, pleuritic pain sometimes may be present, crackles may be heard in the area of embolization, and local wheeze may be heard rarely.
• Multiple pulmonary emboli or thrombi
  • Patients belonging to both the subsets in this category have physical signs of pulmonary hypertension and cor pulmonale.
  • Patients may have elevated jugular venous pressure, right ventricular heave, palpable impulse in the left second intercostal space, right ventricular S3 gallop, systolic murmur over the left sternal border that is louder during inspiration, hepatomegaly, ascites, and dependent pitting edema.
  • These findings are not specific for pulmonary embolism and require a high index of suspicion for pursuing appropriate diagnostic studies.

The most common physical signs in the PIOPED study were as follows⁷ :

• Tachypnea (70%)
• Rales (51%)
• Tachycardia (30%)
• Fourth heart sound (24%)
• Accentuated pulmonic component of the second heart sound (23%)

Fever of less than 39°C may be present in 14% of patients; however, temperature higher than 39.5°C is not from pulmonary embolism. Finally, chest wall tenderness upon palpation, without a history of trauma, may be the sole physical finding in rare cases.

Causes

The causes for pulmonary embolism are multifactorial and are not readily apparent in many cases. The following causes have been described in the literature:

• Venous stasis
  • Venous stasis leads to accumulation of platelets and thrombin in veins.
  • Increased viscosity may occur due to polycythemia and dehydration, immobility, raised venous pressure in cardiac failure, or compression of a vein by a tumor.
• Hypercoagulable states
  • The complex and delicate balance between coagulation and anticoagulation is altered by many diseases, by obesity, after surgery, or by trauma.
  • Concomitant hypercoagulability may be present in disease states where prolonged venous stasis or injury to veins occurs.
  • Hypercoagulable states may be acquired or congenital. Factor V Leiden mutation causing resistance to activated protein C is the most common risk factor. Factor V Leiden mutation is present in up to 5% of the normal population and is the most common cause of familial thromboembolism.
  • Primary or acquired deficiencies in protein C, protein S, and antithrombin III are other risk factors. The deficiency of these natural anticoagulants is responsible for 10% of venous thrombosis in younger people
• Immobilization
  • Immobilization leads to local venous stasis by accumulation of clotting factors and fibrin, resulting in thrombus formation.
  • The risk of pulmonary embolism increases with prolonged bed rest or immobilization of a limb in a cast.
  • Paralysis increases the risk.
• Surgery and trauma
  • Both surgical and accidental trauma predispose patients to venous thromboembolism by activating clotting factors and causing immobility.
  • Fractures of the femur and tibia are associated with the highest risk, followed by pelvic, spinal, and other fractures.
  • Severe burns carry a high risk of DVT or pulmonary embolism.
  • A prospective study by Geerts and colleagues in 1994 indicated that major trauma was associated with a 58% incidence of DVT in the lower extremities and an 18% incidence in proximal veins.¹⁰
  • Pulmonary embolism may account for 15% of all postoperative deaths. Leg amputations and hip, pelvic, and spinal surgery are associated with the highest risk.
• Pregnancy
  • The incidence of thromboembolic disease in pregnancy has been reported to range from 1 case in 200 deliveries to 1 case in 1400 deliveries.
  • Fatal events may occur rarely, 1-2 cases per 100,000 pregnancies.
  • The mechanism of DVT is venous stasis, decreasing fibrinolytic activity, and increased procoagulant factors.
• Oral contraceptives and estrogen replacement
  • Estrogen-containing birth control pills have increased the occurrence of venous thromboembolism in healthy women.
  • The risk is proportional to the estrogen content and is increased in postmenopausal women on hormonal replacement therapy.
  • The relative risk is 3-fold, but the absolute risk is 20-30 cases per 100,000 persons per year.
• Malignancy
  • Malignancy has been identified in 17% of patients with venous thromboembolism.
  • The neoplasms most commonly associated with pulmonary embolism, in descending order of frequency, are pancreatic carcinoma; bronchogenic carcinoma; and carcinomas of the genitourinary tract, colon, stomach, and breast.

• Immobilization
• Travel of 4 hr or more in the past month
• Surgery within the last 3 months
• Malignancy, especially lung cancer
• Current or past history of thrombophlebitis
• Trauma to the lower extremities and pelvis during the past 3 months
• Smoking
• Central venous instrumentation within the past 3 months
• Stroke, paresis, or paralysis
• Prior pulmonary embolism
• Heart failure
• Chronic obstructive pulmonary disease

• Obesity
• Varicose veins
• Inflammatory bowel disease

Differential Diagnoses

Other Problems to Be Considered

Differential diagnoses are extensive, and they should be considered carefully with any patient thought to have pulmonary embolism. These patients also should have an alternate diagnosis confirmed, or pulmonary embolism should be excluded, before discontinuing the workup. Additional problems to be considered include the following:

Musculoskeletal pain
Pleuritis
Costochondritis
Rib fracture
Pericarditis
Angina pectoris
Salicylate intoxication
Hyperventilation
Silicone pulmonary embolism¹²

Workup

Laboratory Studies

Clinical signs and symptoms for pulmonary embolism (PE) are nonspecific; therefore, patients suspected of having pulmonary embolism—because of unexplained dyspnea, tachypnea, or chest pain or the presence of risk factors for pulmonary embolism—must undergo diagnostic tests until the diagnosis is ascertained or eliminated or an alternative diagnosis is confirmed. Further, routine laboratory findings are nonspecific and are not helpful in pulmonary embolism, although they may suggest another diagnosis.

Evidence-based literature supports the practice of determining the clinical probability of pulmonary embolism before proceeding with testing.¹³ A clinical practice guideline from the American Academy of Family Physicians (AAFP) and the American College of Physicians (ACP) recommends that validated clinical prediction rules be used to estimate pretest probability of pulmonary embolism and to interpret test results.^14,15 The guideline, Current diagnosis of venous thromboembolism in primary care, advocates use of the Wells prediction rule for this purpose, but notes that the Wells rule performs better in younger patients without comorbidities or a history of venous thromboembolism.

Table 1. Wells Prediction Rule for Diagnosing Pulmonary Embolism: Clinical Evaluation Table for Predicting Pretest Probability of Pulmonary Embolism

Note: Clinical probability of pulmonary embolism: low 0–1; intermediate 2–6; high >7
Reprinted from Am J Med, Vol 113, Chagnon I, Bounameaux H, Aujesky D, et al, Comparison of two clinical prediction rules and implicit assessment among patients with suspected pulmonary embolism, pp 269-75, Copyright 2002.

Another validated clinical prediction rule for use in the diagnosis of pulmonary embolism is the revised Geneva score.¹⁶ The performance of the revised Geneva score appears equivalent to that of the Wells score.¹⁷

Table 2 The Revised Geneva Score*

Simplified versions of the Wells score and the revised Geneva score have been developed. Initial studies support the validity of these scores, which assign 1 point to each of the criteria.^18,19

• D-dimer testing
  • When clinical prediction rule results indicate that the patient has a low or moderate pretest probability of pulmonary embolism, D-dimer testing is the usual next step.¹³  Negative results on a high-sensitivity D-dimer test in a patient with a low pretest probability of pulmonary embolism indicate a low likelihood of venous thromboembolism and reliably exclude pulmonary embolism. A large prospective randomized trial found that in patients with a low probability of pulmonary embolism who had negative D-dimer results, forgoing additional diagnostic testing was not associated with an increased frequency of symptomatic venous thromboembolism during the subsequent 6 months.²⁰  
  • D-dimer, a degradation product produced by plasmin-mediated proteases of cross-linked fibrin, is measured by a variety of assay types, including quantitative, semiquantitative, and qualitative rapid enzyme-linked immunosorbent assays (ELISAs); quantitative and semiquantitative latex; and whole-blood assays. A systematic review of prospective studies of high methodologic quality concluded that the ELISAs—especially the quantitative rapid ELISA—dominate the comparative ranking among the D-dimer assays for sensitivity and negative likelihood ratio.²¹ The quantitative rapid ELISA has a sensitivity of 0.95 and negative likelihood ratio of 0.13; the latter is similar to that for a normal to near-normal lung scan in patients with suspected pulmonary embolism.
  • D-dimer testing is most reliable for excluding pulmonary embolism in younger patients who have no associated comorbidity or history of venous thromboembolism and whose symptoms are of short duration.¹⁴  D-dimer testing is of questionable value in patients who are older than 80 years, are hospitalized, or have cancer and in pregnant women, because nonspecific elevation of D-dimer concentrations is common in such patients. D-dimer test should not be used when the clinical probability of pulmonary embolism is high, because the test has low negative predictive value in such cases.²²
• Troponins
  • Serum troponin levels can be elevated in up to 50% of patients with a moderate-to-large pulmonary embolism, presumptively due to acute right ventricular myocardial stretch.²³
  • Although not currently recommended as part of the diagnostic workup, studies have shown that elevated troponin levels in the setting of pulmonary embolism correlate with increased mortality.²⁴  Currently, further studies need to be performed to identify subsets of patients with pulmonary embolism who might benefit from this testing.
• Brain natriuretic peptide
  • Although neither sensitive nor specific, patients with pulmonary embolism tend to have higher levels of brain natriuretic peptide (BNP). In one case-control study of 2213 hemodynamically stable patients with suspected acute pulmonary embolism, BNP testing had a sensitivity and specificity of only 60% and 62%, respectively.²⁵
  • Elevated levels of BNP or its precursor, N -terminal pro-brain natriuretic peptide (NT-proBNP), do correlate with an increased risk of subsequent complications and mortality in patients with acute pulmonary embolism. One meta-analysis revealed that patients with a BNP level greater than 100 pg/mL or an NT-proBNP level greater than 600 ng/L had an all-cause in-hospital mortality rate 6- and 16-fold higher than those below these cutoffs, respectively.²⁶ In a second smaller observational study, serum BNP levels greater than 90 pg/mL were associated with a higher rate of complications, such as the need for cardiopulmonary resuscitation, need for mechanical ventilation, need for vasopressor therapy, and death.²⁷
  • BNP testing is not currently recommended as part of the standard evaluation of acute pulmonary embolism, and future studies may aid in defining its role in this setting.
• Arterial blood gases 
  • Arterial blood gas determinations characteristically reveal hypoxemia, hypocapnia, and respiratory alkalosis; however, the predictive value of hypoxemia is quite low.
  • Both the PaO₂ and the calculation of alveolar-arterial oxygen gradient contribute to the diagnosis in a general population thought to have pulmonary embolism.
  • Nonetheless, in high-risk settings such as patients in postoperative states in whom other respiratory conditions can be ruled out, a low PaO₂ in conjunction with dyspnea may have a strong positive predictive value.

Imaging Studies

• Chest radiography
  • The American College of Radiology (ACR) recommends chest radiography as the most appropriate study for ruling out other causes of chest pain in patients with suspected pulmonary embolism.²⁸
  • Initially, the chest radiography findings are normal in most cases of pulmonary embolism. However, in later stages, radiographic signs may include a Westermark sign (dilatation of pulmonary vessels and a sharp cutoff), atelectasis, a small pleural effusion, and an elevated diaphragm.
  • Although chest radiography findings may indicate an alternate diagnosis, this study alone is not sufficient to confirm the diagnosis of pulmonary embolism.

Posteroanterior and lateral chest radiograph findings are normal, which is the usual finding in patients with pulmonary embolism.

A chest radiograph with normal findings in a 64-year-old woman who presented with worsening breathlessness.

A posteroanterior chest radiograph showing a peripheral wedge-shaped infiltrate caused by pulmonary infarction secondary to pulmonary embolism. Hampton hump is a rare and nonspecific finding. Courtesy of Justin Wong, MD.

• Computed tomography
  • CT angiography (CTA) is the initial imaging modality of choice for stable patients with suspected pulmonary embolism. The ACR considers chest CTA the current standard of care for the detection of pulmonary embolism.²⁸
  • In patients with a negative CTA, the likelihood for subsequent thromboembolic events is extremely small.
  • The Christopher study, a prospective trial, used CT as part of a management algorithm for 3306 outpatients with suspected acute pulmonary embolism. Patients in whom the Wells rule indicated that pulmonary embolism was unlikely underwent D-dimer testing; if the result was normal, pulmonary embolism was considered excluded. All other patients underwent multidetector CT arteriography, and pulmonary embolism was considered present or excluded based on the results. Among patients with negative scan results who did not receive anticoagulation therapy, the 3-month incidence of venous thromboembolism was 1.3%; death, possibly from pulmonary embolism, occurred in 0.5%.²⁹
  • Similarly, a meta-analysis published in 2004 reviewed 23 studies reporting on 4657 patients with negative pulmonary CTA results for pulmonary embolism who did not receive anticoagulation. The rate of venous thromboembolism was 1.4% and the rate of fatal pulmonary embolism was 0.51% at 3 months. These results are similar to negative results on conventional pulmonary angiography. These investigators concluded that withholding anticoagulation after negative pulmonary CTA results appears to be safe.³⁰
  • Spiral CT can visualize main, lobar, and segmental pulmonary emboli with a reported sensitivity of greater than 90%. Spiral CT scanning can help detect emboli as small as 2 mm that are affecting up to the seventh border division of the pulmonary artery. A further benefit of spiral CT scanning is that the results may suggest an alternative diagnosis in up to 57% of patients. A significant limitation of spiral CT scanning is that small subsegmental emboli may not be detected.
  • The technique is as follows:
    • Spiral CT examination is performed immediately after infusion of 150-200 mL of 30% contrast material.
    • Scanning is performed from the level of the aortic arch to approximately 2 cm below the level of the inferior pulmonary vein while the patient is holding his or her breath at full inspiration.
    • If the patient is not able to hold his or her breath for 20-30 seconds, scanning may be performed during gentle breathing.
  • Sensitivity and specificity of spiral CT scanning for pulmonary embolism are as follows:
    • The reported sensitivity is 53-100%.
    • The reported specificity is 78-96%.
    • The negative predictive value is 81-100%, and the positive predictive value is 60-100% for detecting emboli in segmental or larger arteries.
  • Positive findings on CT imaging include a central intravascular filling defect within the vessel lumen, eccentric tracking of contrast material around a filling defect, and complete vascular occlusion. Smooth filling defects making an obtuse angle with a vessel wall may represent chronic thrombi or recent recanalization. In the lung parenchyma, signs of pulmonary embolism include oligemia, pulmonary hemorrhage (ground-glass attenuation), and pulmonary infarction (peripheral wedge-shaped pleural-based opacification).
  • Pitfalls include the following:
    • Technically inadequate scans may result from patients' dyspnea and/or obliquely or horizontally oriented vessels within the right middle lobe and left lingula.
    • False filling defects may result from breathing artifact cardiac motion or unilateral extensive air space consolidation as a result of  the significant decrease in blood flow through pulmonary arteries in these areas.
  • Also see Acute Pulmonary Embolism (Helical CT).
• Combined spiral CT scanning for detection of pulmonary embolism and deep venous thrombosis (DVT)
  • A combined CT scan for PE/DVT enhances the utility of spiral CT scanning by further identifying emboli in the deep venous system of the lower extremities or the pelvic veins.
  • Good venous enhancement of the lower extremity veins occurs 2 minutes following lung CT scanning as 5-mm scans are performed at 5-cm intervals from the upper calves to the diaphragm.
  • Alternatively, 1-cm images are performed from the iliac bones to the tibial plateau. The additional radiation dose needs to be considered in the formulation of this protocol. With this technique, up to 4% of patients with negative results on CT scanning examination for pulmonary embolism have been identified to have DVT.

A spiral CT scan shows thrombus in bilateral main pulmonary arteries.

A spiral CT scan shows thrombus in bilateral main pulmonary arteries.

CT scan of the same chest depicted in Image 18. Courtesy of Justin Wong, MD.

• Ventilation-perfusion (V/Q) scanning of the lungs: This is an important diagnostic modality for establishing the diagnosis of pulmonary embolism. However, V/Q scanning should be used only when CT scanning is not available or if the patient has a contraindication to CT scanning or intravenous contrast material.
• New criteria for V/Q scanning diagnosis of pulmonary embolism, from the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) II trial:
  • High probability criteria are as follows:
    • Two large (>75% of a segment) segmental perfusion defects without corresponding ventilation or chest radiographic abnormalities
    • One large segmental perfusion defect and 2 moderate (25-75% of a segment) segmental perfusion defects without corresponding ventilation or radiographic abnormalities
    • Four moderate segmental perfusion defects without corresponding ventilation or chest radiographic abnormalities
  • Intermediate probability criteria are as follows:
    • One moderate to fewer than 2 large segmental perfusion defects without corresponding ventilation or chest radiographic abnormalities
    • Corresponding V/Q defects and radiographic parenchymal opacity in lower lung zone
    • Single moderate matched V/Q defects with normal chest radiographic findings
    • Corresponding V/Q and chest radiography small pleural effusion
    • Difficult to categorize as normal, low, or high probability
  • Low probability criteria are as follows:
    • Multiple matched V/Q defects, regardless of size, with normal chest radiographic findings
    • Corresponding V/Q defects and radiographic parenchymal opacity in upper or middle lung zone
    • Corresponding V/Q defects and large pleural effusion
    • Any perfusion defects with substantially larger radiographic abnormality
    • Defects surrounded by normally perfused lung (stripe sign)
    • More than 3 small (<25% of a segment) segmental perfusion defects with normal chest radiographic findings
    • Nonsegmental perfusion defects (cardiomegaly, aortic impression, enlarged hila)
  • Very low criterion is 3 small (<25% of a segment) segmental perfusion defects with normal chest radiograph findings.
  • Normal finding is no perfusion defects and perfusion outlines the shape of the lung seen on a chest radiograph.
  • In the PIOPED II study, very low-probability V/Q scans in patients whose Wells score indicated low pretest probability of pulmonary embolism reliably excluded pulmonary embolism.³¹

High-probability perfusion lung scan shows segmental perfusion defects in the right upper lobe and subsegmental perfusion defects in right lower lobe, left upper lobe, and left lower lobe.

A normal ventilation scan will make the above-noted defects in Image 5 a mismatch and, hence, a high-probability ventilation-perfusion scan.

Anterior views of perfusion and ventilation scans are shown here. A perfusion defect is present in the left lower lobe, but perfusion to this lobe is intact, making this a high-probability scan.

A segmental ventilation perfusion mismatch evident in a left anterior oblique projection.

• Noninvasive tests for lower extremity DVT
  • These may be helpful in the evaluation of patients who have nondiagnostic V/Q scan patterns of intermediate and low probability.
  • Color-flow Doppler imaging and compression ultrasonography have a high sensitivity (89-100%) and specificity (89-100%) for detection of proximal DVT in symptomatic patients. However, compression ultrasonography has a low sensitivity (38%) and a low positive predictive value (26%) in patients without symptoms of DVT. Patients with positive findings for DVT can be anticoagulated irrespective of their V/Q scan results; other patients must have more invasive investigations performed to definitively rule out pulmonary embolism.
• Pulmonary angiography
  • Pulmonary angiography remains the criterion standard for the diagnosis of pulmonary embolism.
  • Following injection of iodinated contrast, anteroposterior, lateral, and oblique studies are performed on each lung.
  • Positive results consist of a filling defect or sharp cutoff of the affected artery. Nonocclusive emboli are described to have a tram-track appearance.
  • Abnormal findings on V/Q scans performed prior to angiography guide the operator to focus on abnormal areas.
  • Angiography generally is a safe procedure. The mortality rate for patients undergoing this procedure is less than 0.5%, and the morbidity rate is less than 5%.
  • Patients who have long-standing pulmonary arterial hypertension and right ventricular failure are considered high-risk patients.
  • Negative pulmonary angiogram findings, even if false negative,  exclude clinically relevant pulmonary embolism.

A pulmonary angiogram shows the abrupt termination of the ascending branch of the right upper-lobe artery, confirming the diagnosis of pulmonary embolism.

• Magnetic resonance imaging
  • With MRI, evidence of pulmonary emboli may be detected by using standard or gated spin-echo techniques.
  • Pulmonary emboli demonstrate increased signal intensity within the pulmonary artery. By obtaining a sequence of images, this signal that is originating from slow blood flow may be distinguished from pulmonary embolism. However, this remains a problem in pulmonary hypertension.
  • Magnetic resonance angiography is performed following intravenous administration of gadolinium. Gadolinium-based contrast agents (gadopentetate dimeglumine [Magnevist], gadobenate dimeglumine [MultiHance], gadodiamide [Omniscan], gadoversetamide [OptiMARK], gadoteridol [ProHance]) have been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or magnetic resonance angiography scans.
  • NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness.
  • MRI has a sensitivity of 85% and specificity of 96% for central, lobar, and segmental emboli; MRI is inadequate for the diagnosis of subsegmental emboli.
• Echocardiography
  • This modality generally has limited accuracy in the diagnosis of pulmonary embolism.
  • Transesophageal echocardiography may identify central pulmonary embolism, and the sensitivity for central pulmonary embolism is reported to be 82%.
  • Overall sensitivity and specificity for central and peripheral pulmonary embolism is 59% and 77%.
  • Echocardiography may demonstrate right ventricular dysfunction in acute pulmonary embolism, predicting a higher mortality and possible benefit from thrombolytic therapy. Vanni et al reported that a right ventricular strain pattern is associated with a worse short-term outcome.³²

Other Tests

• Electrocardiography
  • The most common ECG abnormalities of pulmonary embolism are tachycardia and nonspecific ST-T wave abnormalities. These findings are not sensitive or specific enough to aid in the diagnosis of pulmonary embolism.
  • The classic finding of right-sided heart strain demonstrated by an S1-Q3-T3 pattern is observed in only 20% of patients with proven pulmonary embolism.

Treatment

Medical Care

Immediate full anticoagulation is mandatory for all patients suspected to have deep vein thrombosis (DVT) or pulmonary embolism (PE). Diagnostic investigations should not delay empirical anticoagulant therapy. Current guidelines recommend starting unfractionated heparin (UFH), low molecular weight heparin (LMWH) or fondaparinux (all grade 1A) in addition to an oral anticoagulant (warfarin) at the time of diagnosis, and to discontinue UH, LMWH, or fondaparinux only after the international normalized ratio (INR) is 2.0 for at least 24 hours, but no sooner than 5 days after warfarin therapy has been started (grade 1C recommendation).³³  The recommended duration of UH, LMWH, and fondaparinux is based on evidence suggesting that the relatively long half-life of factor II, along with the short half-lives of protein C and protein S, may provoke a paradoxical hypercoagulable state if these agents are discontinued prematurely.

• Thrombolytic therapy
  • Thrombolytic therapy should be considered for patients who are hemodynamically unstable, patients who have right-sided heart strain, and high-risk patients with underlying poor cardiopulmonary reserve.
  • Although most studies demonstrate superiority of thrombolytic therapy with respect to resolution of radiographic and hemodynamic abnormalities within the first 24 hours, this advantage disappears 7 days after treatment. Controlled clinical trials have not demonstrated benefit in terms of reduced mortality rates or earlier resolution of symptoms when currently compared with heparin.
  • Until randomized clinical trials demonstrate a clear morbidity or mortality benefit, the role of thrombolytic therapy in the management of acute pulmonary embolism remains controversial. The currently accepted indications for thrombolytic therapy include hemodynamic instability or right ventricular dysfunction demonstrated on echocardiography.
• Goals of anticoagulation therapy
  • The efficacy of heparin therapy depends on achieving a critical therapeutic level of heparin within the first 24 hours of treatment. The critical therapeutic level of heparin is 1.5 times the baseline control value or the upper limit of normal range of the activated partial thromboplastin time (aPTT).
  • This level of anticoagulation is expected to correspond to a heparin blood level of 0.2-0.4 U/mL by the protamine sulfate titration assay and 0.3-0.6 by the antifactor X assay.
  • Each laboratory should establish the minimal therapeutic level for heparin, as measured by the aPTT, to coincide with a heparin blood level of at least 0.2 U/mL for each batch of thromboplastin reagent being used.
  • If intravenous UFH is chosen, an initial bolus of 80 U/kg or 5000 U followed by an infusion of 18 U/kg/h or 1300 U/h should be given, with the goal of rapidly achieving and maintaining the aPTT at levels that correspond to therapeutic heparin levels. Fixed-dose and monitored regimens of subcutaneous UFH are available and  are acceptable alternatives.
• Low molecular weight heparin
  • Current guidelines for patients with acute nonmassive pulmonary embolism recommend LMWH over UFH (grade 1A). In patients with massive pulmonary embolism, if concerns regarding subcutaneous absorption arise, severe renal failure exists, or if thrombolytic therapy is being considered, intravenous UFH is the recommended form of initial anticoagulation (grade 2C).³³
  • LMWHs have many advantages over UFH. These agents have a greater bioavailability, can be administered by subcutaneous injections, and have a longer duration of anticoagulant effect.
  • A fixed dose of LMWH can be used, and laboratory monitoring of aPTT is not necessary.
  • Trials comparing LMWH with UFH have shown that LMWH is at least as effective and as safe as UFH.
  • The studies have not pointed to any significant differences in recurrent thromboembolic events, major bleeding, or mortality between the 2 types of heparin.
  • LMWH can be administered safely in an outpatient setting. This has lead to the development of programs in which clinically stable patients with pulmonary embolism are treated at home, at substantial cost savings.
• Fondaparinux
  • Fondaparinux is a synthetic polysaccharide derived from the antithrombin binding region of heparin. Fondaparinux catalyzes factor Xa inactivation by antithrombin without inhibiting thrombin.
  • Fondaparinux has not been directly compared with subcutaneous UFH or LMWH, but one randomized open-label study of 2213 patients with symptomatic pulmonary embolism compared once daily subcutaneous fondaparinux with intravenous UFH. The 2 regimens were found to have similar rates of recurrent pulmonary embolism, bleeding, and death.³⁴
  • With the exception of patients presenting with massive pulmonary embolism (defined by hemodynamic compromise), LMWH or fondaparinux is recommended over intravenous UFH. This is because of a more predictable bioavailability, more rapid onset of full anticoagulant effect, and benefit of not typically needing to monitor anticoagulant effect.
  • However, in cases in which an anticoagulant with a shorter half-life is more desirable (ie, patients at particularly high risk of bleeding) or in patients with impaired renal function, intravenous UFH may be preferred (grade 2C).³³
• Oral anticoagulant therapy
  • The anticoagulant effect of warfarin is mediated by the inhibition of vitamin K–dependent factors, which are II, VII, IX, and X. The peak effect does not occur until 36-72 hours after drug administration, and the dosage is difficult to titrate.
  • A prothrombin time ratio is expressed as an INR and is monitored to assess the adequacy of warfarin therapy. The recommended therapeutic range for venous thromboembolism is an INR of 2-3. This level of anticoagulation markedly reduces the risk of bleeding without the loss of effectiveness. Initially, INR measurements are performed on a daily basis; once the patient is stabilized on a specific dose of warfarin, the INR determinations may be performed every 1-2 weeks or at longer intervals.
• Duration of anticoagulation
  • A patient with a first thromboembolic event occurring in the setting of reversible risk factors such as immobilization, surgery, or trauma, should receive warfarin therapy for at least 3 months. Among patients with idiopathic (or unprovoked) first events, 2 studies have compared 6 versus 3 months of anticoagulant therapy and no difference in the rate of recurrence was observed in either study.^35,36 The current recommendation is anticoagulation for at least 3 months in these patients, and the need for extending the duration of anticoagulation should be reevaluated at that time.
  • Warfarin treatment for longer than 6 months is indicated in patients with recurrent venous thromboembolism or in those in whom a continuing risk factor for venous thromboembolism exists, including malignancy, immobilization, or morbid obesity.
  • Patients who have pulmonary embolism and preexisting irreversible risk factors, such as deficiency of antithrombin III, protein S and C, factor V Leiden mutation, or the presence of antiphospholipid antibodies, should be placed on long-term anticoagulation.
• Compression stockings: For patients who have had a proximal DVT, elastic compression stockings with a pressure of 30-40 mm Hg at the ankle for 2 years following the diagnosis is recommended (grade 1A) to reduce the risk of postphlebitic syndrome.

Surgical Care

The current grade 1A recommendation is that patients with acute pulmonary embolism should not routinely receive vena cava filters in addition to anticoagulants.³³

Inferior vena cava (IVC) interruption by the insertion of an IVC filter (Greenfield filter) is only indicated in the following settings:  

• Patients with acute venous thromboembolism who have an absolute contraindication to anticoagulant therapy (eg, recent surgery, hemorrhagic stroke, significant active or recent bleeding)
• Patients with massive pulmonary embolism who survived but in whom recurrent embolism invariably will be fatal
• Patients who have objectively documented recurrent venous thromboembolism, adequate anticoagulant therapy notwithstanding

An ideal IVC filter should have the following characteristics³⁷ :  

• Easy and safe placement by percutaneous technique
• Biocompatible and mechanically stable
• Ability to trap emboli without causing occlusion of the vena cava

One large trial has shown that during the first 12 days after insertion of IVC filters, significantly fewer patients had recurrent pulmonary embolism. However, following a 2-year follow-up, no significant differences in survival rates existed between the 2 groups. Furthermore, significantly higher rates of recurrent DVT occurred among patients who received an IVC filter. Other complications of IVC filters include proximal migration of the filter into the right-sided heart chambers and perforation of the IVC.³⁸

Activity

Activity is recommended as tolerated. Early ambulation is recommended over bed rest when feasible (grade 1A recommendation).

Medication

Immediate therapeutic anticoagulation is initiated for patients with suspected deep venous thrombosis (DVT) or pulmonary embolism (PE). Anticoagulation therapy with heparin reduces mortality rates from 30% to less than 10%. Thrombolytic therapy is recommended for 3 groups of patients: (1) those patients who are hemodynamically unstable, (2) those who have right-sided heart strain, and (3) those who have limited cardiopulmonary reserve.

Chronic anticoagulation is critical to prevent relapse of DVT or pulmonary embolism following initial heparinization. The optimum duration of anticoagulation has not been well studied and is controversial. The general consensus is that a significant reduction in recurrence is associated with 3-6 months of anticoagulation.

Thrombolytics

Thrombolysis is indicated for hemodynamically unstable patients with pulmonary embolism. Thrombolysis dramatically improves acute cor pulmonale. Thrombolytic therapy has replaced surgical embolectomy as the treatment for hemodynamically unstable patients with massive pulmonary embolism.

Thrombolytic regimens currently in use for pulmonary embolism include 2 forms of recombinant tissue-plasminogen activators, alteplase (t-PA) and reteplase (r-PA), along with urokinase and streptokinase. The comparative clinical trials have shown that administration of a 1-h infusion of alteplase is more rapidly effective than urokinase or streptokinase over a 12-h period. The safety and efficacy of different thrombolytic agents is comparable. Streptokinase may cause anaphylaxis, hypotension, and other adverse reactions, leading to the cessation of therapy in many cases.

Rarely, empiric thrombolysis may be indicated in selected patients who are hemodynamically unstable, eg, the clinical likelihood of pulmonary embolism is overwhelming and the patient's condition is rapidly deteriorating (with the possibility of imminent death). In such patients, the possible risk of severe complications from thrombolysis should be carefully evaluated against the potential benefits.

Reteplase (Retavase)

Second-generation recombinant plasminogen activator that forms plasmin after facilitating cleavage of endogenous plasminogen. In clinical trials, shown to be comparable to t-PA in achieving TIMI, 2 or 3 patency, at 90 min. Given as a single bolus or as 2 boluses administered 30 min apart.
As a fibrinolytic agent, seems to work faster than its forerunner, t-PA, and may be more effective in patients with larger clot burdens. Also reported to be more effective than other agents in lysis of older clots. Two major differences help explain these improvements. Compared with t-PA, r-PA does not bind fibrin so tightly, allowing the drug to diffuse more freely through the clot. Another advantage seems to be that it does not compete with plasminogen for fibrin-binding sites, allowing plasminogen at the site of the clot to be transformed into clot-dissolving plasmin.
The FDA has not approved r-PA for use in patients with PE. Studies for PE have used the same dose approved by the FDA for coronary artery fibrinolysis.

Dosing

Adult

10 U IV over 2 min, followed 30 min later by second dose of 10 U IV; alternatively, 20 U IV bolus as single dose

Pediatric

Not established

Interactions

May increase effects of warfarin, heparin, and aspirin

Contraindications

Documented hypersensitivity; uncontrolled hypertension; recent intracranial surgery; malformation of aneurysm; bleeding diathesis; history of cerebrovascular accident

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution with cardiovascular arrhythmias, hypotension, perfusion arrhythmias, recent major surgery, and puncture of noncompressible vessels; cerebrovascular disease; GI or GU bleeding; systolic BP 180 mm Hg and/or diastolic BP 110 mm Hg; acute pericarditis, subacute bacterial endocarditis; hemostatic defects, including those secondary to severe hepatic or renal disease, hepatic dysfunction, pregnancy, diabetic hemorrhagic retinopathy, or other hemorrhagic ophthalmic conditions; septic thrombophlebitis or occluded AV cannula at seriously infected site and >75 y
Heparin should never be given concurrently when urokinase, streptokinase, or APSAC are used (heparin is started when the thrombin time or the aPTT is at or below a level that is twice the normal control value); heparin should be given concurrently with r-PA for treatment of AMI; neither heparin nor aspirin should be given concurrently when used for acute ischemic stroke; coagulation studies should be performed 4 h after initiation of fibrinolytic therapy

Alteplase (Activase)

Used in management of AMI, acute ischemic stroke, and PE. Drug most often used to treat patients with PE in the ED. Usually given as a front-loaded infusion over 90-120 min. FDA-approved for this indication. Most ED personnel are familiar with its use because it is widely used for treatment of patients with AMI. An accelerated 90-min regimen is widely used, and most believe it is both safer and more effective than the approved 2-h infusion. Accelerated regimen dose is based on patient weight.
Heparin therapy should be instituted or reinstituted near the end of or immediately following infusion, when the aPTT or thrombin time returns to twice normal or less.

Dosing

Adult

100 mg IV infusion over 2 h
>67 kg: 15 mg IV bolus followed by 50 mg infused over 30 min; then 35 mg infused over 60 min; not to exceed 100 mg
<67 kg: 15 mg IV bolus, followed by 0.75 mg/kg infused over 30 min; not to exceed 50 mg; then 0.5 mg/kg over 60 min; not to exceed 35 mg

Pediatric

Administer as in adults

Interactions

Drugs that alter platelet function (eg, aspirin, dipyridamole, abciximab) may increase risk of bleeding prior to, during, or after t-PA therapy; may give heparin with and after t-PA infusions to reduce risk of rethrombosis; either heparin or t-PA may cause bleeding complications

Contraindications

Documented hypersensitivity; active internal bleeding; cerebrovascular accident or stroke within last 2 mo; intracranial or intraspinal surgery or trauma, intracranial hemorrhage on pretreatment evaluation; suspicion of subarachnoid hemorrhage; intracranial neoplasm; arteriovenous malformation or aneurysm; bleeding diathesis; severe uncontrolled hypertension

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Monitor for bleeding, especially at arterial puncture sites, with coadministration of vitamin K antagonists; doses >0.9 mg/kg may cause ICH
Heparin should never be given concurrently when urokinase, streptokinase, or APSAC are used (heparin is started when the thrombin time or aPTT is at or below a level that is twice the normal control value); heparin should be given concurrently with r-PA for treatment of AMI; neither heparin nor aspirin should be given concurrently when used for acute ischemic stroke; coagulation studies should be performed 4 h after initiation of fibrinolytic therapy; caution in cardiovascular arrhythmias, hypotension, perfusion arrhythmias, recent major surgery, and puncture of noncompressible vessels; cerebrovascular disease; GI or GU bleeding; systolic BP 180 mm Hg and/or diastolic BP 110 mm Hg; acute pericarditis, subacute bacterial endocarditis; hemostatic defects, including those secondary to severe hepatic or renal disease, hepatic dysfunction, pregnancy, diabetic hemorrhagic retinopathy, or other hemorrhagic ophthalmic conditions; septic thrombophlebitis or occluded AV cannula at seriously infected site and >75 y

Urokinase (Abbokinase)

Direct plasminogen activator produced by human fetal kidney cells grown in culture. Acts on the endogenous fibrinolytic system and converts plasminogen to the enzyme plasmin, which, in turn, degrades fibrin clots, fibrinogen, and other plasma proteins. Advantage is that this agent is nonantigenic; however, more expensive than streptokinase and, thus, limits use. When used for localized fibrinolysis, given as local catheter-directed continuous infusion directly into area of thrombus with no loading dose. When used for PE, loading dose is necessary.

Dosing

Adult

Loading dose: 250,000 U IV over 30 min
Maintenance dose: Infuse 100,000 U/h IV for 12-72 h

Pediatric

Loading dose: 4400 U/kg IV over 10 min
Maintenance dose: Infuse 4400 U/kg/h IV for 12-72 h

Interactions

Thrombolytic enzymes, alone or in combination with anticoagulants and antiplatelets, may increase risk of bleeding complications

Contraindications

Documented hypersensitivity; internal bleeding; recent trauma; history of intracranial or intraspinal surgery or trauma; cerebrovascular accident; intracranial neoplasm

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Monitor for bleeding, especially at arterial puncture sites, with coadministration of vitamin K antagonists
Heparin should never be given concurrently when urokinase, streptokinase, or APSAC are used (heparin is started when the thrombin time or aPTT is at or below a level that is twice the normal control value); neither heparin nor aspirin should be given concurrently when used for acute ischemic stroke; coagulation studies should be performed 4 h after initiation of fibrinolytic therapy; caution in cardiovascular arrhythmias, hypotension, perfusion arrhythmias, recent major surgery, and puncture of noncompressible vessels; cerebrovascular disease; GI or GU bleeding; systolic BP 180 mm Hg and/or diastolic BP 110 mm Hg; acute pericarditis, subacute bacterial endocarditis; hemostatic defects, including those secondary to severe hepatic or renal disease, hepatic dysfunction, pregnancy, diabetic hemorrhagic retinopathy, or other hemorrhagic ophthalmic conditions; septic thrombophlebitis or occluded AV cannula at seriously infected site and >75 y

Streptokinase (Kabikinase, Streptase)

Acts with plasminogen to convert plasminogen to plasmin. Plasmin degrades fibrin clots, fibrinogen, and other plasma proteins. Increase in fibrinolytic activity that degrades fibrinogen levels for 24-36 h takes place with IV infusion of streptokinase. Highly antigenic. Highly likely that treatment will be interrupted due to allergic drug reactions.
Chills, fever, nausea, and skin rashes are frequent (up to 20%). Blood pressure and heart rate drop in approximately 10% of cases during or shortly after treatment.
Late complications may include purpura, respiratory distress syndrome, serum sickness, Guillain-Barré syndrome, vasculitis, and renal or hepatic dysfunction.

Dosing

Adult

Loading dose: 2000 U/kg IV over 10 min
Maintenance: 2000 U/lb/h IV for 24 h

Pediatric

Administer as in adults

Interactions

Antifibrinolytic agents may decrease effects of streptokinase; heparin, warfarin, and aspirin may increase risk of bleeding

Contraindications

Documented hypersensitivity; active internal bleeding; intracranial neoplasm; aneurysm; diathesis; severe uncontrolled arterial hypertension; prior exposure to drug within the past 4 y or in recent streptococcal infection

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Monitor for bleeding, especially at arterial puncture sites, with coadministration of vitamin K antagonists
Heparin should never be given concurrently when urokinase, streptokinase, or APSAC are used (heparin is started when the thrombin time or the aPTT is at or below a level that is twice the normal control value); neither heparin nor aspirin should be given concurrently when used for acute ischemic stroke; coagulation studies should be performed 4 h after initiation of fibrinolytic therapy; caution in cardiovascular arrhythmias, hypotension, perfusion arrhythmias, recent major surgery, and puncture of noncompressible vessels; cerebrovascular disease; GI or GU bleeding; systolic BP 180 mm Hg and/or diastolic BP 110 mm Hg; acute pericarditis, subacute bacterial endocarditis; hemostatic defects, including those secondary to severe hepatic or renal disease, hepatic dysfunction, pregnancy, diabetic hemorrhagic retinopathy, or other hemorrhagic ophthalmic conditions; septic thrombophlebitis or occluded AV cannula at seriously infected site and >75 y

Anticoagulants

Heparin augments activity of the natural anticoagulant antithrombin III and prevents conversion of fibrinogen to fibrin. Full-dose LMWH or unfractionated IV heparin should be initiated at the first suspicion of DVT or pulmonary embolism. Heparin does not dissolve an existing clot, but it does prevent clot propagation and embolization. Recurrence or extension of DVT and pulmonary embolism may occur despite therapeutic anticoagulation with heparin.

With proper dosing, several LMWH products have been found to be safer and more effective than UFH for prophylaxis and treatment of patients with DVT and pulmonary embolism. Not necessary or useful to monitor aPTT while using LMWH. Drug is most active in tissue phase, and, as opposed to UFH, LMWH does not exert most of its effects on coagulation factor IIa.

Many different LMWH products are currently available. Because of the pharmacokinetic differences, dosing and interval of administration is highly product-specific. Presently, 3 LMWH products are available in the United States (enoxaparin, dalteparin, ardeparin). Enoxaparin is the only one that is approved by the FDA for treatment of patients with DVT. The FDA has approved all 3 for DVT prophylaxis at a lower dose. LMWH administered via subcutaneous route is preferred for commencing anticoagulation therapy. Maintenance therapy with warfarin usually is initiated simultaneously. The weight-adjusted heparin dosing regimens have proven to be efficacious for treatment of patients with DVT and pulmonary embolism and are endorsed by the experts.

Enoxaparin (Lovenox)

Enhances inhibition of factor Xa and thrombin by increasing antithrombin III activity. In addition, preferentially increases inhibition of factor Xa. First LMWH in United States. Only LMWH approved by FDA for treatment and prophylaxis of DVT and PE. Widely used in pregnancy, although clinical trials are not yet available to demonstrate that it is as safe as UFH.

Dosing

Adult

DVT/PE: 1 mg/kg SC q12h or 1.5 mg/kg SC qd
Prophylaxis of DVT: 30 mg SC q12h
Prophylaxis in abdominal surgery: 40 mg SC qd, first dose given 2 h prior to surgery

Pediatric

DVT/PE: 1 mg/kg SC q 12h

Interactions

Platelet inhibitors or oral anticoagulants (eg, dipyridamole, salicylates, aspirin, NSAIDs, sulfinpyrazone, ticlopidine) may increase risk of bleeding

Contraindications

Documented hypersensitivity; major bleeding; thrombocytopenia

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

If thromboembolic event occurs despite LMWH prophylaxis, discontinue drug and initiate alternate therapy; elevation of hepatic transaminase levels may occur but is reversible; heparin-associated thrombocytopenia (HAT) may occur; 1 mg protamine sulfate reverses effect of approximately 1 mg enoxaparin if significant bleeding complications develop

Dalteparin (Fragmin)

LMWH with many similarities to enoxaparin but with a different dosing schedule. Approved for DVT prophylaxis in patients undergoing abdominal surgery. Except in overdoses, no utility exists in checking PT or aPTT because aPTT does not correlate with anticoagulant effect of fractionated LMWH.

Dosing

Adult

Prophylaxis in abdominal surgery: 2500 U SC qd

Pediatric

Not established

Interactions

Platelet inhibitors or oral anticoagulants (eg, dipyridamole, salicylates, aspirin, NSAIDs, sulfinpyrazone, ticlopidine) may increase risk of bleeding

Contraindications

Documented hypersensitivity; major bleeding; thrombocytopenia

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

If thromboembolic event occurs despite LMWH prophylaxis, discontinue drug and initiate alternate therapy; elevation of hepatic transaminase levels may occur but is reversible; HAT may occur with fractionated LMWHs; 1 mg protamine sulfate reverses effect of approximately 100 U of dalteparin

Ardeparin (Normiflo)

LMWH recently released in United States for DVT prophylaxis in patients undergoing hip and knee surgery. Except in overdoses, no utility exists in checking PT or aPTT because the aPTT does not correlate with anticoagulant effect of fractionated LMWH.

Dosing

Adult

DVT prophylaxis in patients undergoing hip and knee surgery: 50 U/kg SC q12h

Pediatric

Not established

Interactions

Platelet inhibitors or oral anticoagulants (eg, dipyridamole, salicylates, aspirin, NSAIDs, sulfinpyrazone, ticlopidine) may increase risk of bleeding

Contraindications

Documented hypersensitivity; major bleeding; thrombocytopenia

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Reversible elevation of hepatic transaminase levels may occur; HAT has been observed with fractionated LMWH; if necessary, 1 mg protamine can neutralize 100 U of ardeparin

Heparin (Hep-Lock, Liquaemin)

Augments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. Does not actively lyse but is able to inhibit further thrombogenesis. Prevents reaccumulation of clot after spontaneous fibrinolysis. When UFH is used, the aPTT should not be checked until 6 h after the initial heparin bolus because an extremely high or low value during this time should not provoke any action.

Dosing

Adult

Initial bolus: 120-140 U/kg IV or approximately 10,000 U/70 kg; adjust dose according to desired aPTT
Initial infusion: 20 U/kg/h IV; adjust dose according to desired aPTT
If the aPTT is low (<1.5-times control value), rebolus with 5000 U and increase the drip by 10%
If aPTT is high (>2.5-times control value), decrease drip by 10%
If aPTT is extremely high (>100 s), hold drip for 1 h and decrease drip by 10%

Pediatric

Loading dose: 100 U/kg/h IV
Maintenance infusion: 15-25 U/kg/h IV
Increase dose by 2-4 U/kg/h IV q6-8h prn using aPTT results

Interactions

Digoxin, nicotine, tetracycline, and antihistamines may decrease effects; NSAIDs, ASA, dextran, dipyridamole, and hydroxychloroquine may increase heparin toxicity

Contraindications

Documented hypersensitivity; subacute bacterial endocarditis; active bleeding; history of heparin-induced thrombocytopenia

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

In neonates, preservative-free heparin is recommended to avoid possible toxicity (gasping syndrome) by benzyl alcohol, which is used as a preservative; caution in severe hypotension and shock; most important risk associated with UFH is that it is ineffective because of insufficient doses; may cause hemorrhagic complications and can trigger immune thrombotic thrombocytopenia 1-2 wk after the beginning of treatment; HAT is very serious, causes widespread thrombosis that is refractory to treatment, and can be fatal if not recognized quickly and managed appropriately; if significant bleeding complications develop, 15 mg protamine (infused over 3 min) usually reverses the anticoagulant effect of UFH

Warfarin (Coumadin)

Interferes with hepatic synthesis of vitamin K–dependent coagulation factors. Used for prophylaxis and treatment of venous thrombosis, PE, and thromboembolic disorders. Never administer to patients with thrombosis until after fully anticoagulated with heparin (first few days of warfarin therapy produce a hypercoagulable state). Failing to anticoagulate with heparin before starting warfarin causes clot extension and recurrent thromboembolism in approximately 40% of patients, compared with 8% of those who receive full-dose heparin before starting warfarin. Heparin should be continued for the first 5-7 d of oral warfarin therapy, regardless of the PT time, to allow time for depletion of procoagulant vitamin K–dependent proteins.
Tailor dose to maintain an INR in the range of 2.5-3.5. Risk of serious bleeding (including hemorrhagic stroke) is approximately constant when the INR is 2.5-4.5 but rises dramatically when the INR is >5. In the United Kingdom, higher INR target of 3-4 often is recommended.
Evidence suggests that 6 mo of anticoagulation reduces rate of recurrence to half of the recurrence rate observed when only 6 wk of anticoagulation is given. Long-term anticoagulation is indicated for patients with an irreversible underlying risk factor and recurrent DVT or recurrent PE.
Procoagulant vitamin K–dependent proteins are responsible for a transient hypercoagulable state when warfarin is first started and stopped. This is the phenomenon that occasionally causes warfarin-induced necrosis of large areas of skin or of distal appendages. Heparin is always used to protect against this hypercoagulability when warfarin is started; but, when warfarin is stopped, the problem resurfaces, causing an abrupt temporary rise in the rate of recurrent venous thromboembolism.
At least 186 different foods and drugs reportedly interact with warfarin. Clinically significant interactions have been verified for a total of 26 common drugs and foods, including 6 antibiotics and 5 cardiac drugs. Every effort should be made to keep the patient adequately anticoagulated at all times because procoagulant factors recover first when warfarin therapy is inadequate.
Patients who have difficulty maintaining adequate anticoagulation while taking warfarin may be asked to limit their intake of foods that contain vitamin K.
Foods that have moderate to high amounts of vitamin K include Brussels sprouts, kale, green tea, asparagus, avocado, broccoli, cabbage, cauliflower, collard greens, liver, soybean oil, soybeans, certain beans, mustard greens, peas (black-eyed peas, split peas, chick peas), turnip greens, parsley, green onions, spinach, and lettuce.

Dosing

Adult

5-15 mg/d PO qd initial; adjust dose according to desired INR

Pediatric

0.05-0.34 mg/kg/d PO; adjust dose according to desired INR

Interactions

Drugs that may decrease anticoagulant effects include griseofulvin, carbamazepine, glutethimide, estrogens, nafcillin, phenytoin, rifampin, barbiturates, cholestyramine, colestipol, vitamin K, spironolactone, oral contraceptives, and sucralfate; medications that may increase anticoagulant effects of warfarin include oral antibiotics, phenylbutazone, salicylates, sulfonamides, chloral hydrate, clofibrate, diazoxide, anabolic steroids, ketoconazole, ethacrynic acid, miconazole, nalidixic acid, sulfonylureas, allopurinol, chloramphenicol, cimetidine, disulfiram, metronidazole, phenylbutazone, phenytoin, propoxyphene, sulfonamides, gemfibrozil, acetaminophen, and sulindac

Contraindications

Documented hypersensitivity; severe liver or kidney disease; open wounds or GI ulcers; malignant hypertension; pregnancy

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Do not switch brands after achieving therapeutic response; caution in active tuberculosis or diabetes; patients with protein C or S deficiency are at risk of developing skin necrosis

Fondaparinux sodium (Arixtra)

Synthetic anticoagulant that works by inhibiting factor Xa, a key component involved in blood clotting. Provides highly predictable response. Bioavailability is 100%. Has a rapid onset of action and a half-life of 14-16 h, allowing for sustained antithrombotic activity over 24-h period. Does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation.

Dosing

Adult

2.5 mg SC qd

Pediatric

Not established

Interactions

None reported; increased risk of bleeding possible with concurrent administration of platelet inhibitors, oral anticoagulants, or thrombolytic agents

Contraindications

Documented hypersensitivity; seriously impaired kidney function or in patients who weigh <110 lb; patients given spinal anesthesia or spinal puncture

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

When spinal anesthesia or spinal puncture used, may develop blood clot in spine, which can result in long-term or permanent paralysis

Follow-up

Deterrence/Prevention

Heparin prophylaxis

The incidence of venous thrombosis, pulmonary embolism (PE), and death can be significantly reduced by embracing a prophylactic strategy in high-risk patients. Prevention of deep vein thrombosis (DVT) in the lower extremities inevitably reduces the frequency of pulmonary embolism; therefore, populations at risk must be identified, and safe and efficacious prophylactic modalities should be used. The risk groups identified in clinical practice and the prophylaxis recommended by the Sixth Consensus Conference on Antithrombotic Therapy are described in the Table.

Prophylaxis Against Venous Thromboembolism

Compression stockings provide a compression of 30-40 mm Hg gradient and are a safe and effective therapy to prevent venous thromboembolism in patients who are at high risk when heparin therapy is not desirable or is contraindicated. These devices provide a gradient of compression that is highest at the toes and gradually decreases to the level of the thigh. This mechanism reduces the capacitative venous volume by approximately 70% and increases the measured velocity of blood flow by a factor of 5 or more in lower extremity veins.

A meta-analysis calculated a DVT risk ratio of 0.28 for gradient compression stockings (compared with no prophylaxis) in patients undergoing abdominal surgery, gynecologic surgery, or neurosurgery. Other studies have reported that gradient compression stockings and low molecular weight heparin (LMWH) were the most effective modalities in reducing the incidence of DVT after hip surgery.

The universal white stockings, known as antiembolic stockings or Ted stockings, produce a maximum compression of only 18 mm Hg. Ted stockings rarely are fitted in such a way as to provide adequate gradient compression to the deep venous system. Therefore, Ted stockings have no proven efficacy in the prevention of DVT and pulmonary embolism.

Gradient compression pantyhose (30-40 mmHg) are available in pregnant sizes. They are recommended by many specialists for all women who are pregnant because they prevent DVT and reduce or prevent the development of varicose veins.

Although strict bed rest was recommended in the past for acute DVT to reduce the risk of pulmonary embolism, a study has shown no benefit from prescribing bed rest. Therefore, strict bed rest for 5 days is not justified if adequate therapy with LMWH and adequate compression is assured.

Complications

• Sudden cardiac death
• Obstructive shock
• Pulseless electrical activity
• Atrial or ventricular arrhythmias
• Secondary pulmonary arterial hypertension
• Cor pulmonale
• Severe hypoxemia
• Right-to-left intracardiac shunt
• Lung infarction
• Pleural effusion
• Paradoxical embolism

Prognosis

• The prognosis of patients with pulmonary embolism depends on 2 factors: (1) the underlying disease state and (2) appropriate diagnosis and treatment.
• Most patients treated with anticoagulants do not develop long-term sequelae upon follow-up evaluation.
• At 5 days of anticoagulant therapy, 36% of lung scan defects are resolved; at 2 weeks, 52% are resolved; at 3 months, 73% are resolved.
• The mortality rate in patients with undiagnosed pulmonary embolism is 30%.
• Elevated plasma levels of natriuretic peptides (brain natriuretic peptide and N -terminal pro-brain natriuretic peptide) have been associated with higher mortality in patients with pulmonary embolism.³⁹ In one study, levels of N -terminal pro-brain natriuretic peptide greater than 500 ng/L was independently associated with central pulmonary embolism and was a possible predictor of death from pulmonary embolism.⁴⁰  
• In the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) (PIOPED) study, the 1-year mortality rate was 24%.⁷ The deaths occurred due to cardiac disease, recurrent pulmonary embolism, infection, and cancer.
• The risk of recurrent pulmonary embolism is due to the recurrence of proximal venous thrombosis; approximately 17% of patients with recurrent pulmonary embolism were found to have proximal DVT.
• In a small proportion of patients, pulmonary embolism does not resolve; hence, chronic thromboembolic pulmonary arterial hypertension results.

Patient Education

For excellent patient education resources, visit eMedicine's Lung and Airway Center and Circulatory Problems Center. Also, see eMedicine's patient education articles Pulmonary Embolism and Blood Clot in the Legs.

Miscellaneous

Medicolegal Pitfalls

Pulmonary embolism (PE) is an extremely common disorder. It presents with nonspecific clinical features and requires specialized investigations for confirmation of diagnosis. Therefore, many patients die from unrecognized pulmonary embolism. The other common pitfalls are as follows:  

• Disregarding patient's complaints of unexplained dyspnea as anxiety or hyperventilation
• Blaming complaints of unexplained chest pain on musculoskeletal pain
• Failing to recognize, diagnose, and treat deep vein thrombosis (DVT)
• Failing to initiate an appropriate diagnostic workup in patients with symptoms consistent with pulmonary embolism
• Failing to initiate therapeutic anticoagulant therapy with heparin in patients suspected to have pulmonary embolism, before the V/Q scan or other investigations

The role of thrombolytic therapy in patients who are hemodynamically stable remains uncertain. No particular diagnostic strategy appears to be superior to another at present. More clinical studies are needed to evaluate the utility of new diagnostic approaches for pulmonary embolism. The availability of the diagnostic tests, the expertise of the radiologists, cost-effective analysis, and local traditions appear to be the considerations in the workup of a patient suspected to have pulmonary embolism.

Special Concerns

• Pregnancy
  • The risk of venous thromboembolism is increased during pregnancy and the postpartum period. Pregnant women who are in a hypercoagulable state or have had previous venous thromboembolism should receive prophylactic anticoagulation during pregnancy.
  • Pulmonary embolism is the leading cause of death in pregnancy. Guidelines by the professional societies make this difficult diagnosis easier and reduce the risks of radiation to the fetus. If the patient has a low pretest probability for pulmonary embolism and a normal D-dimer test result, clinical exclusion from further investigations is recommended. When the suspicion is high, the patients should have bilateral leg Doppler assessment. If the results are positive, the patient should be treated for pulmonary embolism. If the results are negative, CT pulmonary angiography is the next step. To rule out contrast-induced hypothyroidism, all neonates exposed to the iodinated contrast in utero should have their serum thyrotropin  level checked in the first week of life.
  • Pregnant patients diagnosed with DVT or pulmonary embolism are treated with unfractionated heparin or LMWH throughout their pregnancy. Warfarin is contraindicated because it crosses the placental barrier and can cause fetal malformations. Therefore, either subcutaneous unfractionated heparin or LMWH at full anticoagulation doses should be continued until delivery. Women experiencing a thromboembolic event during pregnancy should receive therapeutic treatment with unfractionated heparin or LMWH during pregnancy, with anticoagulation continuing for 4-6 weeks postpartum, and for a total of at least 6 months.
• Heparin-induced thrombocytopenia
  • Heparin-induced thrombocytopenia (HIT) is a transient prothrombotic disorder initiated by heparin.
  • Main features are (1) thrombocytopenia resulting from immunoglobulin G–mediated platelet activation and (2) in vivo thrombin generation and increased risk of venous and arterial thrombosis.
  • The highest frequency of HIT, 5%, has been reported in post-orthopedic surgery patients receiving up to 2 weeks of unfractionated heparin. HIT occurred in approximately 0.5% of post-orthopedic surgery patients receiving LMWH for up to 2 weeks.
  • HIT may manifest clinically as extension of the thrombus or formation of new arterial thrombosis. HIT should be suspected whenever the patient's platelet count falls to less than 100,000/µL or less than 50% of the baseline value, generally after 5-15 days of heparin therapy. The definitive diagnosis is made by performing a platelet activation factor assay.
  • The treatment of patients who develop HIT is to stop all heparin products, including catheter flushes and heparin-coated catheters, and to initiate an alternative nonheparin anticoagulant, even when thrombosis is not clinically apparent. Preferred agents include direct thrombin inhibitors such as lepirudin or argatroban. Start warfarin while the patient receives an alternative nonheparin anticoagulant and only when the platelet count has recovered to at least 100,000/µL, preferably 150,000/µL.
• Resistance to heparin
  • Few patients with venous thromboembolism require large doses of heparin for achieving an optimal activated partial thromboplastin time (aPTT). These patients have increased plasma concentrations of factor VIII and heparin-binding proteins. Increased factor VIII concentration causes a dissociation between aPTT and plasma heparin values. The aPTT is suboptimal, but patients have adequate heparin levels upon protamine titration. This commonly occurs in patients with a concomitant inflammatory disease.
  • Monitoring the antifactor Xa assay results in this situation is safe and effective and results in less escalation of the heparin dose when compared with monitoring with aPTT. Whenever a therapeutic level of aPTT cannot be achieved with large doses of unfractionated heparin administration, either determination of plasma heparin concentration or therapy with LMWH should be instituted.
• Elderly individuals
  • Pulmonary embolism is increasingly prevalent among elderly patients, yet the diagnosis is missed more often in this population because respiratory symptoms often are dismissed as being chronic.
  • Even when the diagnosis is made, appropriate therapy frequently is inappropriately withheld because of bleeding concerns.
  • An appropriate diagnostic workup and therapeutic anticoagulation with a careful risk-to-benefit assessment is recommended in this patient population.
• Future research
  • The advances over the past several decades have significantly improved diagnostic abilities and have refined the treatment of patients with pulmonary embolism. However, several areas need further research and properly conducted therapeutic trials. The role of LMWH and the optimal duration of anticoagulant therapy in different subgroups of patients with venous thromboembolism require further study.
  • Future studies should determine whether less intense warfarin therapy (international normalized ratio [INR] <2), which will result in less bleeding, is effective in preventing recurrences.
  • Whether drugs that inhibit the action of thrombin (eg, hirudin) are useful in treating patients with venous thromboembolic disease needs to be determined by future trials.

Multimedia

Media file 1: A large pulmonary artery thrombus in a hospitalized patient who died suddenly.

Media file 2: Pulmonary embolism was identified as the cause of death in a patient who developed shortness of breath while hospitalized for hip joint surgery. This is a close-up view.

Media file 3: Lung infarction secondary to pulmonary embolism occurs rarely.

Media file 4: Posteroanterior and lateral chest radiograph findings are normal, which is the usual finding in patients with pulmonary embolism.

Media file 5: High-probability perfusion lung scan shows segmental perfusion defects in the right upper lobe and subsegmental perfusion defects in right lower lobe, left upper lobe, and left lower lobe.

Media file 6: A normal ventilation scan will make the above-noted defects in Image 5 a mismatch and, hence, a high-probability ventilation-perfusion scan.

Media file 7: Anterior views of perfusion and ventilation scans are shown here. A perfusion defect is present in the left lower lobe, but perfusion to this lobe is intact, making this a high-probability scan.

Media file 8: A segmental ventilation perfusion mismatch evident in a left anterior oblique projection.

Media file 9: A pulmonary angiogram shows the abrupt termination of the ascending branch of the right upper-lobe artery, confirming the diagnosis of pulmonary embolism.

Media file 10: A chest radiograph with normal findings in a 64-year-old woman who presented with worsening breathlessness.

Media file 11: This perfusion scan shows bilateral perfusion defects. The ventilation scan findings were normal; therefore, these are mismatches, and this is a high-probability scan.

Media file 12: A spiral CT scan shows thrombus in bilateral main pulmonary arteries.

Media file 13: A spiral CT scan shows thrombus in bilateral main pulmonary arteries.

Media file 14: Ultrasound shows the thrombus in the distal superficial saphenous vein, which is under the artery.

Media file 15: A lack of respiratory variation in the Doppler waveform of the popliteal vein.

Media file 16: This ultrasound shows the thrombus tip in the superficial femoral vein, with a small amount of flow around it. The color flow deep into the superficial femoral vein is from the profunda femoris vein.

Media file 17: An ultrasound shows the thrombus filling the superficial femoral vein; the noncompressibility further confirms the diagnosis.

Media file 18: A posteroanterior chest radiograph showing a peripheral wedge-shaped infiltrate caused by pulmonary infarction secondary to pulmonary embolism. Hampton hump is a rare and nonspecific finding. Courtesy of Justin Wong, MD.

Media file 19: CT scan of the same chest depicted in Image 18. Courtesy of Justin Wong, MD.

References

1. Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med. Jul 28 2003;163(14):1711-7. [Medline]. [Full Text].

2. Burge AJ, Freeman KD, Klapper PJ, Haramati LB. Increased diagnosis of pulmonary embolism without a corresponding decline in mortality during the CT era. Clin Radiol. Apr 2008;63(4):381-6. [Medline].

3. DeMonaco NA, Dang Q, Kapoor WN, Ragni MV. Pulmonary embolism incidence is increasing with use of spiral computed tomography. Am J Med. Jul 2008;121(7):611-7. [Medline].

4. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. Nov 15 2005;143(10):697-706. [Medline].

5. Kuklina EV, Meikle SF, Jamieson DJ, et al. Severe obstetric morbidity in the United States: 1998-2005. Obstet Gynecol. Feb 2009;113(2 Pt 1):293-9. [Medline].

6. Schneider D, Lilienfeld DE, Im W. The epidemiology of pulmonary embolism: racial contrasts in incidence and in-hospital case fatality. J Natl Med Assoc. Dec 2006;98(12):1967-72. [Medline]. [Full Text].

7. Worsley DF, Alavi A. Comprehensive analysis of the results of the PIOPED Study. Prospective Investigation of Pulmonary Embolism Diagnosis Study. J Nucl Med. Dec 1995;36(12):2380-7. [Medline]. [Full Text].

8. Amesquita M, Cocchi MN, Donnino MW. Pulmonary Embolism Presenting as Flank Pain: A Case Series. J Emerg Med. Mar 26 2009;[Medline].

9. Carrascosa MF, Batan AM, Novo MF. Delirium and pulmonary embolism in the elderly. Mayo Clin Proc. 2009;84(1):91-2. [Medline]. [Full Text].

10. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. Dec 15 1994;331(24):1601-6. [Medline].

11. Stein PD, Beemath A, Matta F, et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med. Oct 2007;120(10):871-9. [Medline]. [Full Text].

12. Restrepo CS, Artunduaga M, Carrillo JA, et al. Silicone pulmonary embolism: report of 10 cases and review of the literature. J Comput Assist Tomogr. Mar-Apr 2009;33(2):233-7. [Medline].

13. Tapson VF. Acute pulmonary embolism. N Engl J Med. Mar 6 2008;358(10):1037-52. [Medline].

14. [Guideline] Qaseem A, Snow V, Barry P, et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med. Jan-Feb 2007;5(1):57-62. [Medline].

15. [Guideline] Qaseem A, Snow V, Barry P, et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. Mar 20 2007;146(6):454-8. [Medline].

16. [Best Evidence] Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. Feb 7 2006;144(3):165-71. [Medline]. [Full Text].

17. Klok FA, Kruisman E, Spaan J, et al. Comparison of the revised Geneva score with the Wells rule for assessing clinical probability of pulmonary embolism. J Thromb Haemost. Jan 2008;6(1):40-4. [Medline].

18. Douma RA, Gibson NS, Gerdes VE, et al. Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thromb Haemost. Jan 2009;101(1):197-200. [Medline].

19. [Best Evidence] Klok FA, Mos IC, Nijkeuter M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med. Oct 27 2008;168(19):2131-6. [Medline].

20. Kearon C, Ginsberg JS, Douketis J, et al. An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med. Jun 6 2006;144(11):812-21. [Medline]. [Full Text].

21. Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med. Apr 20 2004;140(8):589-602. [Medline]. [Full Text].

22. Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med. Dec 25 2008;359(26):2804-13. [Medline].

23. Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol. Nov 1 2000;36(5):1632-6. [Medline].

24. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. Jul 24 2007;116(4):427-33. [Medline].

25. Söhne M, Ten Wolde M, Boomsma F, Reitsma JB, Douketis JD, Buller HR. Brain natriuretic peptide in hemodynamically stable acute pulmonary embolism. J Thromb Haemost. Mar 2006;4(3):552-6. [Medline].

26. Cavallazzi R, Nair A, Vasu T, Marik PE. Natriuretic peptides in acute pulmonary embolism: a systematic review. Intensive Care Med. Dec 2008;34(12):2147-56. [Medline].

27. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation. May 27 2003;107(20):2545-7. [Medline].

28. [Guideline] Bettmann MA, Lyders EM, Yucel EK, et al. ACR Appropriateness Criteria acute chest pain—suspected pulmonary embolism. American College of Radiology. National Guideline Clearinghouse. 2006;April 13, 2009. [Full Text].

29. van Belle A, Buller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA. Jan 11 2006;295(2):172-9. [Medline]. [Full Text].

30. Moores LK, Jackson WL Jr, Shorr AF, Jackson JL. Meta-analysis: outcomes in patients with suspected pulmonary embolism managed with computed tomographic pulmonary angiography. Ann Intern Med. Dec 7 2004;141(11):866-74. [Medline]. [Full Text].

31. Gottschalk A, Stein PD, Sostman HD, Matta F, Beemath A. Very low probability interpretation of V/Q lung scans in combination with low probability objective clinical assessment reliably excludes pulmonary embolism: data from PIOPED II. J Nucl Med. Sep 2007;48(9):1411-5. [Medline]. [Full Text].

32. [Best Evidence] Vanni S, Polidori G, Vergara R, et al. Prognostic value of ECG among patients with acute pulmonary embolism and normal blood pressure. Am J Med. Mar 2009;122(3):257-64. [Medline].

33. [Guideline] Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. Jun 2008;133(6 Suppl):454S-545S. [Medline].

34. Garcia D, Ageno W, Libby E. Update on the diagnosis and management of pulmonary embolism. Br J Haematol. Nov 2005;131(3):301-12. [Medline].

35. Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ. Mar 31 2007;334(7595):674. [Medline].

36. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. May 22 2001;103(20):2453-60. [Medline].

37. Ballew KA, Philbrick JT, Becker DM. Vena cava filter devices. Clin Chest Med. Jun 1995;16(2):295-305. [Medline].

38. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. Feb 12 1998;338(7):409-15. [Medline].

39. Cavallazzi R, Nair A, Vasu T, Marik PE. Natriuretic peptides in acute pulmonary embolism: a systematic review. Intensive Care Med. Dec 2008;34(12):2147-56. [Medline].

40. Alonso-Martinez JL, Urbieta-Echezarreta M, Anniccherico-Sanchez FJ, Abinzano-Guillen ML, Garcia-Sanchotena JL. N-terminal pro-B-type natriuretic peptide predicts the burden of pulmonary embolism. Am J Med Sci. Feb 2009;337(2):88-92. [Medline].

41. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. Mar 26 2009;113(13):2878-87. [Medline].

42. Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary embolism. JAMA. Sep 27 1976;236(13):1477-80. [Medline].

43. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med. Jul 15 1993;119(2):104-9. [Medline].

44. Bulger CM, Jacobs C, Patel NH. Epidemiology of acute deep vein thrombosis. Tech Vasc Interv Radiol. Jun 2004;7(2):50-4. [Medline].

45. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. May 7 1992;326(19):1240-5. [Medline].

46. Davey NC, Smith TP, Hanson MW, Lee VS, Stackhouse DJ, Coleman RE. Ventilation-perfusion lung scintigraphy as a guide for pulmonary angiography in the localization of pulmonary emboli. Radiology. Oct 1999;213(1):51-7. [Medline].

47. Deitelzweig S, Jaff MR. Medical management of venous thromboembolic disease. Tech Vasc Interv Radiol. Jun 2004;7(2):63-7. [Medline].

48. Drucker EA, Rivitz SM, Shepard JA, et al. Acute pulmonary embolism: assessment of helical CT for diagnosis. Radiology. Oct 1998;209(1):235-41. [Medline].

49. Egermayer P, Town GI, Turner JG, Heaton DC, Mee AL, Beard ME. Usefulness of D-dimer, blood gas, and respiratory rate measurements for excluding pulmonary embolism. Thorax. Oct 1998;53(10):830-4. [Medline].

50. Ginsberg JS. Management of venous thromboembolism. N Engl J Med. Dec 12 1996;335(24):1816-28. [Medline].

51. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest. Nov 1998;114(5 Suppl):524S-530S. [Medline].

52. Ginsberg JS, Wells PS, Kearon C, et al. Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. Ann Intern Med. Dec 15 1998;129(12):1006-11. [Medline].

53. Gottschalk A, Stein PD, Goodman LR, Sostman HD. Overview of Prospective Investigation of Pulmonary Embolism Diagnosis II. Semin Nucl Med. Jul 2002;32(3):173-82. [Medline]. [Full Text].

54. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. Nov 1998;114(5 Suppl):445S-469S. [Medline].

55. Howarth DM, Booker JA, Voutnis DD. Diagnosis of pulmonary embolus using ventilation/perfusion lung scintigraphy: more than 0.5 segment of ventilation/perfusion mismatch is sufficient. Intern Med J. May 2006;36(5):281-8. [Medline].

56. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. Jan 28 1982;306(4):189-94. [Medline].

57. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. Oct 18 1979;301(16):855-8. [Medline].

58. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med. Nov 10 1997;157(20):2317-21. [Medline].

59. Hull RD, Raskob GE, Ginsberg JS, et al. A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med. Feb 14 1994;154(3):289-97. [Medline].

60. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. Aug 1992;152(8):1589-95. [Medline].

61. Katz DS, Hon M. Current DVT imaging. Tech Vasc Interv Radiol. Jun 2004;7(2):55-62. [Medline].

62. Kluetz PG, White CS. Acute pulmonary embolism: imaging in the emergency department. Radiol Clin North Am. Mar 2006;44(2):259-71, ix. [Medline].

63. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost. Feb 2000;83(2):209-11. [Medline].

64. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. Mar 14 1996;334(11):677-81. [Medline].

65. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. Dec 1990;98(6):1473-9. [Medline].

66. Marks PW. Management of thromboembolism in pregnancy. Semin Perinatol. Aug 2007;31(4):227-31. [Medline].

67. Matthews S. Short communication: imaging pulmonary embolism in pregnancy: what is the most appropriate imaging protocol?. Br J Radiol. May 2006;79(941):441-4. [Medline].

68. Mayo JR, Remy-Jardin M, Muller NL, et al. Pulmonary embolism: prospective comparison of spiral CT with ventilation-perfusion scintigraphy. Radiology. Nov 1997;205(2):447-52. [Medline].

69. Moser KM. Venous thromboembolism. Am Rev Respir Dis. Jan 1990;141(1):235-49. [Medline].

70. Mullins MD, Becker DM, Hagspiel KD, Philbrick JT. The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism. Arch Intern Med. Feb 14 2000;160(3):293-8. [Medline].

71. O'Neill JM, Wright L, Murchison JT. Helical CTPA in the investigation of pulmonary embolism: a 6-year review. Clin Radiol. Sep 2004;59(9):819-25. [Medline].

72. Ramzi DW, Leeper KV. DVT and pulmonary embolism: Part I. Diagnosis. Am Fam Physician. Jun 15 2004;69(12):2829-36. [Medline].

73. Ramzi DW, Leeper KV. DVT and pulmonary embolism: Part II. Treatment and prevention. Am Fam Physician. Jun 15 2004;69(12):2841-8. [Medline].

74. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. Feb 1 2000;132(3):227-32. [Medline].

75. Rosendaal FR. Venous thrombosis: prevalence and interaction of risk factors. Haemostasis. Dec 1999;29 Suppl S1:1-9. [Medline].

76. Schaefer-Prokop C, Prokop M. MDCT for the diagnosis of acute pulmonary embolism. Eur Radiol. Nov 2005;15 Suppl 4:D37-41. [Medline].

77. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. Feb 6 1997;336(6):393-8. [Medline].

78. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. Sep 4 1997;337(10):663-9. [Medline].

79. Stein PD, Hull RD, Saltzman HA, Pineo G. Strategy for diagnosis of patients with suspected acute pulmonary embolism. Chest. May 1993;103(5):1553-9. [Medline].

80. Stein PD, Saltzman HA, Weg JG. Clinical characteristics of patients with acute pulmonary embolism. Am J Cardiol. Dec 15 1991;68(17):1723-4. [Medline].

81. Tapson VF. Pulmonary embolism: the diagnostic repertoire. Chest. Sep 1997;112(3):578-80. [Medline].

82. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism. Br Med J. Mar 2 1974;1(5904):343-7. [Medline].

83. Warkentin TE. Think of HIT. Hematology. 2006;1:408-414.

84. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. Jun 2008;133(6 Suppl):340S-380S. [Medline].

85. Wells PS. Advances in the diagnosis of venous thromboembolism. J Thromb Thrombolysis. Feb 2006;21(1):31-40. [Medline].

86. Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med. Dec 15 1998;129(12):997-1005. [Medline].

Keywords

pulmonary embolism, pulmonary emboli, venous thromboembolism, PE, obstructive shock, deep vein thrombosis, deep venous thrombosis, DVT, hemodynamic collapse, acute pulmonary infarction, pulmonary hypertension, cor pulmonale

pleuritic chest pain, hemoptysis, venous stasis, polycythemia, immobility, hypercoagulability, factor V Leiden mutation, pancreatic carcinoma, bronchogenic carcinoma, carcinoma of the genitourinary tract, colon cancer, breast cancer, congestive heart failure, stroke, obesity, varicose veins, inflammatory bowel disease

Contributor Information and Disclosures

Author

Nader Kamangar, MD, FACP, FCCP, FAASM,, Associate Professor of Clinical Medicine, Director of Hospitalist/Intensivist Program, Division of Pulmonary, Critical Care and Sleep Medicine, David Geffen School of Medicine at University of California Los Angeles; Associate Director, Combined Pulmonary and Critical Care Fellowship Program, Cedars-Sinai/Olive View-UCLA/West Los Angeles Veterans Affairs Medical Center
Nader Kamangar, MD, FACP, FCCP, FAASM, is a member of the following medical societies: American Academy of Sleep Medicine, American Association of Bronchology, American College of Chest Physicians, American College of Physicians, American Lung Association, American Medical Association, American Thoracic Society, California Thoracic Society, and Society of Critical Care Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Mark S McDonnell, MD, MBA, Cardiology Fellow, University of Southern California
Mark S McDonnell, MD, MBA is a member of the following medical societies: American College of Physicians, American Heart Association, and American Medical Association
Disclosure: Nothing to disclose.

Sat Sharma, MD, FRCPC, Professor and Head, Division of Pulmonary Medicine, Department of Internal Medicine, University of Manitoba; Site Director, Respiratory Medicine, St Boniface General Hospital
Sat Sharma, MD, FRCPC is a member of the following medical societies: American Academy of Sleep Medicine, American College of Chest Physicians, American College of Physicians-American Society of Internal Medicine, American Thoracic Society, Canadian Medical Association, Royal College of Physicians and Surgeons of Canada, Royal Society of Medicine, Society of Critical Care Medicine, and World Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Gregory Tino, MD, Director of Pulmonary Outpatient Practices, Associate Professor, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Medical Center and Hospital
Gregory Tino, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Gregg T Anders, DO, Medical Director, Great Plains Regional Medical Command , Brook Army Medical Center; Clinical Associate Professor, Department of Internal Medicine, Division of Pulmonary Disease, University of Texas Health Science Center at San Antonio
Gregg T Anders, DO is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society
Disclosure: Nothing to disclose.

CME Editor

Timothy D Rice, MD, Associate Professor, Departments of Internal Medicine and Pediatrics and Adolescent Medicine, Saint Louis University School of Medicine
Timothy D Rice, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Physicians
Disclosure: Nothing to disclose.

Chief Editor

Zab Mosenifar, MD, Director, Division of Pulmonary and Critical Care Medicine, Director, Women's Guild Pulmonary Disease Institute, Executive Vice Chair, Department of Medicine, Cedars Sinai Medical Center; Professor of Medicine, David Geffen School of Medicine at UCLA
Zab Mosenifar, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, and American Thoracic Society
Disclosure: Nothing to disclose.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)